Table 6.
Baseline CTC counts detected using the GILUPI CellCollector, EPISPOT assay and CellSearch® system and clinical characteristics of 85 patients with localized PCa at baseline, according to survival during the follow-up period.
| Variable | Survivors | Non-Survivors | p |
|---|---|---|---|
| CTC (GILUPI), median (range) | 1 (0–7) | 0.5 (0–5) | 0.085 |
| CTC (GILUPI), n (%) | 36/57 (63%) | 14/28 (50%) | 0.178 |
| CTC (EPISPOT), median (range) | 1 (0–4) | 0.5 (0–25) | 0.897 |
| CTC (EPISPOT), n (%) | 32/56 (57%) | 13/26 (50%) | 0.356 |
| CTC (CellSearch®), median (range) | 0 (0–54) | 0 (0–3) | 0.027 |
| CTC (CellSearch®), n (%) | 4/49 (8%) | 6/21 (29%) | 0.035 |
| CTC (any assay), n (%) | 49/57 (86%) | 23/28 (82%) | 0.435 |
| PSA (ng/mL), median (range) | 29.3 (3.9–136.9) | 24.1 (0.5–191.0) | 0.086 |
| PSA ≥ 20 ng/mL, n (%) | 47/57 (82%) | 19/28 (68%) | 0.108 |
| Gleason Sum, median (range) | 7 (6–9) | 7 (6–9) | 0.690 |
| Gleason Sum ≥ 8, n (%) | 12/57 (21%) | 7/28 (25%) | 0.440 |
| cT ≥ 2c, n (%) | 21/57 (37%) | 14/27 (52%) | 0.143 |